| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
AbbVie Inc (NYSE: ABBV)
ABBV Technical Analysis
4
| As on 9th Jun 2023 ABBV STOCK Price closed @ 138.18 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 146.68 & Sell for SHORT-TERM with Stoploss of 139.59 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ABBVSTOCK Price
| Open | 137.56 | Change | Price | % |
| High | 139.19 | 1 Day | 0.54 | 0.39 |
| Low | 137.08 | 1 Week | 0.22 | 0.16 |
| Close | 138.18 | 1 Month | -10.69 | -7.18 |
| Volume | 4359500 | 1 Year | 8.23 | 6.33 |
| 52 Week High 174.96 | 52 Week Low 129.95 | ||||
NYSE USA Most Active Stocks
| DDR | 15.44 | -4.46% |
| NIO | 7.73 | -0.77% |
| TWTR | 53.70 | 0.66% |
| CVNA | 19.07 | -21.30% |
| BACA-U | 302.00 | 0.67% |
| PLTR | 15.02 | -1.12% |
| F | 13.74 | 1.18% |
| CS | 0.89 | 1.14% |
| RPAI | 13.15 | -3.17% |
| AUY | 5.85 | -0.68% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| ABBV Daily Charts |
ABBV Intraday Charts |
Whats New @ Bazaartrend |
ABBV Free Analysis |
|
|
ABBV Important Levels Intraday
| RESISTANCE | 142.25 |
| RESISTANCE | 140.94 |
| RESISTANCE | 140.14 |
| RESISTANCE | 139.33 |
| SUPPORT | 137.03 |
| SUPPORT | 136.22 |
| SUPPORT | 135.42 |
| SUPPORT | 134.11 |
ABBV Forecast May 2024
| 4th UP Forecast | 174.72 |
| 3rd UP Forecast | 163 |
| 2nd UP Forecast | 155.76 |
| 1st UP Forecast | 148.51 |
| 1st DOWN Forecast | 127.85 |
| 2nd DOWN Forecast | 120.6 |
| 3rd DOWN Forecast | 113.36 |
| 4th DOWN Forecast | 101.64 |
ABBV Weekly Forecast
| 4th UP Forecast | 145.25 |
| 3rd UP Forecast | 142.98 |
| 2nd UP Forecast | 141.58 |
| 1st UP Forecast | 140.18 |
| 1st DOWN Forecast | 136.18 |
| 2nd DOWN Forecast | 134.78 |
| 3rd DOWN Forecast | 133.38 |
| 4th DOWN Forecast | 131.11 |
ABBV Forecast2024
| 4th UP Forecast | 230 |
| 3rd UP Forecast | 200.55 |
| 2nd UP Forecast | 182.35 |
| 1st UP Forecast | 164.15 |
| 1st DOWN Forecast | 112.21 |
| 2nd DOWN Forecast | 94.01 |
| 3rd DOWN Forecast | 75.81 |
| 4th DOWN Forecast | 46.36 |
AbbVie Inc ( NYSE USA Symbol : ABBV )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ABBV Business Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service